The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

DNA-Encoded Libraries: Platforms and Services Market

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    133

  • View Count
    8007

Example Insights

DNA-Encoded Libraries -Platforms and Service Providers DNA-Encoded Libraries -Market Landscape DNA-Encoded Libraries -Geographical Distribution
DNA-Encoded Libraries -Collaborations DNA-Encoded Libraries -Licensing Deals

 

Overview

The process of drug development, beginning from the discovery of a molecule to its commercial launch, takes around 10-15 years and capital investments worth USD 4-10 billion. It is a well-known fact that only a small proportion of molecules, which are selected for further investigation during the initial stages of research, are actually translated into product candidates. Given the complexities involved in the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, in 2019, the R&D spending was estimated to be around USD 182 billion; over 16,000 drug molecules were reportedly evaluated during the year. The industry is presently under tremendous pressure not only to identify ways to mitigate the risks of failure of drug discovery programs but also to meet the expectations of a growing patient population.

DNA-encoded libraries (also known as DELs), owing to their advantages (such as library size, cost and equipment needs) over high-throughput screening, have demonstrated to be a sophisticated combinatorial drug discovery tool for synthesis and screening of large collections of small molecule compounds. Interestingly, DNA-encoded libraries encompassing as high as 40 trillion different molecules have been developed, enabling screening, hit identification and discovery of pharmacological leads (including macrocycles, natural products and small molecules) against undruggable and unique targets using a single library and accelerating the process of drug development. Moreover, introduction of automated screening of small organic ligands using DNA-encoded chemical libraries has enabled identification of potential lead molecules within a time duration of 10 days.

Several mid-sized to large companies have undertaken initiatives towards building in-house DNA-encoded library technology. In addition, players have forged strategic alliances with service providers for accessing the latter’s DNA-encoded libraries for the purpose of drug discovery. The growing number of drug discovery projects, coupled to the rapid progression of molecules through various stages of drug discovery, is expected to continue to increase demand for such advanced drug discovery tools.

Scope of the Report

The “DNA-Encoded Libraries: Platforms and Services Market” report features an extensive study of the current landscape and the untapped opportunities these DNA-encoded likely to bring in the field of drug discovery. In addition to other elements, the report includes:

  • An overview of the current market landscape of DNA-encoded libraries, featuring details on the type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. 
  • An overview of the landscape of DNA-encoded library developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.
  • A detailed analysis of the partnerships related to DNA-encoded libraries, which have been established in the recent past, covering research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.
  • Elaborate profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of the company, information on its service portfolio, DNA-encoded library portfolio, recent developments and an informed future outlook.
  • A brief overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available). It also features company snapshots for each of the above-mentioned companies 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA-encoded libraries developers’ market and its evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of DNA-encoded libraries with information on the evolution of these libraries, advantages over other conventional drug discovery methods and the challenges associated with the same. It also features a brief discussion on the opportunities and the likely future trends in this field.

Chapter 4 provides a detailed overview of the current market landscape of DNA-encoded libraries, featuring information on type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. In addition, the chapter provides  an overview of DNA-encoded libraries developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.

Chapter 5 features an in-depth analysis and discussion on the various collaborations and partnerships inked between the players in the recent past; these include research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.

Chapter 6 provides detailed profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of company, information on its services associated with their DNA-Encoded library, recent developments and an informed future outlook.

Chapter 7 presents a case study on the therapeutic target(s) against which the DNA-encoded libraries are capable of identifying potential leads. Examples of such targets include undruggable cancer targets (special focus on GPCRs), DNA repair targets (special focus on PARP inhibitors) and other targets (such as alpha-1-acid glycoprotein (AGP), carbonic anhydrase IX, mitogen-activated protein kinase 14 (MAPK14), Neurokinin 3 (NK3), receptor‐interacting protein 1 kinase (RIP1), soluble epoxide hydrolase (sEH) and interleukin 2).

Chapter 8 presents overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available). It also features company snapshots for each of the above-mentioned companies. 

Chapter 9 presents an insightful market forecast analysis, highlighting likely growth of DNA-encoded libraries market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. 

Chapter 10 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of the DNA-encoded library screening approach.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market. 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development

3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment Based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Library-based Screening

3.3.4. Hit-to-Lead
3.3.5. Lead Optimization

3.4. Overview of DNA-Encoded Libraries
3.4.1. Historical Evolution
3.4.2. Encoding Strategies for Library Construction
3.4.3. Comparison of Traditional Libraries and DNA-Encoded Libraries
3.4.4. Key Advantages
3.4.5. Challenges and Limitations

3.5. Future Perspectives and Opportunity Areas

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA-Encoded Libraries: Overall Market Landscape
4.2.1. Analysis by Library Size
4.2.2. Analysis by Type of Pharmacological Lead
4.2.3. Analysis by Method of Library Synthesis
4.2.4. Analysis by Therapeutic Target
4.2.5. Analysis by Therapeutic Area

4.3. DNA-Encoded Libraries: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location
4.3.4. Analysis by Type of Service Offered
4.4. DNA-Encoded Libraries: Supporting Companies

5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models

5.3. DNA-Encoded Libraries: Recent Partnerships and Collaborations
5.3.1. Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year of Partnership and Type of Partner
5.3.4. Most Active Players: Analysis by Number of Partnerships
5.3.5. Most Popular DNA-Encoded Libraries: Analysis by Number of Partnerships
5.3.6. Regional Analysis
5.3.6.1. Most Active Players: Analysis by Local and International Agreements
5.3.6.2. Intercontinental and Intracontinental Agreements

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. HitGen
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.2.1. HitGen’s DNA-Encoded Libraries
6.2.3. Recent Developments and Future Outlook

6.3. X-Chem
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.2.1. X-Chem’s DNA-Encoded Libraries
6.3.3. Recent Developments and Future Outlook

6.4. Vipergen
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.2.1. Vipergen’s DNA-Encoded Libraries
6.4.3. Recent Developments and Future Outlook

6.5. DyNAbind
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.2.1. DyNAbind’s DNA-Encoded Libraries
6.5.3. Recent Developments and Future Outlook

7. CASE STUDY: LIKELY BIOLOGICAL TARGETS FOR DRUG DISCOVERY USING DNA-ENCODED LIBRARIES
7.1. Chapter Overview
7.2. Undruggable Cancer Targets
7.2.1. G protein-coupled receptors (GPCRs)
7.2.2. GPCRs Targeting Drugs: List of Clinical / Preclinical Molecules

7.3. DNA Repair Targets
7.3.1. poly ADP ribose polymerase (PARP) Inhibitors: Overview
7.3.2. PARP Inhibitors: List of Clinical / Preclinical Molecules

7.4. Other Targets

8. BIG PHARMA INITIATIVES: DNA-ENCODED LIBRARIES
8.1. Chapter Overview
8.2. Top Pharmaceutical Companies
8.3. Amgen
8.3.1. Company Snapshot
8.3.2. Initiatives by Amgen

8.4. AstraZeneca
8.4.1. Company Snapshot
8.4.2. Initiatives by AstraZeneca

8.5. GSK
8.5.1. Company Snapshot
8.5.2. Initiatives by GSK

8.6. Novartis 
8.6.1. Company Snapshot
8.6.2. Initiatives by Novartis

8.7. Pfizer
8.7.1. Company Snapshot
8.7.2. Initiatives by Pfizer

8.8. Roche
8.8.1. Company Snapshot
8.8.2. Initiatives by Roche

9. DNA-ENCODED LIBRARY MARKET: OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Input Data
9.3. Forecast Methodology
9.4. DNA-Encoded Libraries Licensing Market: Upfront and Milestone Payments, 2020, 2025 And 2030
9.5. DNA-Encoded Libraries Market: Additional Opportunity

10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1. Drug Discovery and Development Timeline
Figure 3.2. Drug Discovery Process
Figure 3.3. Concept of DNA-Encoded Libraries
Figure 3.4. Historical Evolution of DNA-Encoded Libraries
Figure 3.5. Encoding Strategies for Constructing DNA-Encoded Libraries 
Figure 3.6. Comparison of Traditional Libraries and DNA-Encoded Libraries
Figure 3.7. Advantages of DNA-Encoded Libraries 
Figure 3.8. Limitations of DNA-Encoded Libraries
Figure 4.1. DNA-Encoded Libraries: Distribution by Library Size
Figure 4.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead 
Figure 4.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
Figure 4.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
Figure 4.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
Figure 4.6. DNA-Encoded Libraries: Distribution by Year of Establishment
Figure 4.7. DNA-Encoded Libraries: Distribution by Company Size
Figure 4.8. DNA-Encoded Libraries: Distribution by Geographical Location 
Figure 4.9. DNA-Encoded Libraries: Distribution by Year of Establishment, Company Size and Geographical Location 
Figure 4.10. DNA-Encoded Libraries: Distribution by Type of Service Offered  
Figure 4.11. DNA-Encoded Libraries: Geographical Landscape of Developers by Type of Service Offering
Figure 5.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019 (till October)
Figure 5.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 
Figure 5.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner 
Figure 5.5. Most Active Players: Distribution by Number of Partnerships
Figure 5.6. Most Popular Technologies: Distribution by Number of Partnerships
Figure 5.7. Most Active Players: Geographical Distribution by Number of Partnerships 
Figure 5.8. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 6.1. HitGen: Service Portfolio
Figure 6.2. HitGen: DNA-Encoded Library Synthesis
Figure 6.3. HitGen: DNA-Encoded Library Steps
Figure 6.4. X-Chem: DNA-Encoded Library Synthesis
Figure 6.5. Vipergen: Service Portfolio
Figure 6.6. Vipergen: DNA-Encoded Library Synthesis 
Figure 6.7. Vipergen: MedChem HTS versus YoctoReactor
Figure 6.8. DyNAbind: Service Portfolio
Figure 8.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.1. Licensing Agreements: Distribution of Financial Components
Figure 9.2. Library Licensing Deal: Payment Structure
Figure 9.3. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
Figure 9.4. Case Study: Popular Drug Discovery Methods, 2016-2017

List Of Tables

Table 4.1. DNA-Encoded Libraries: Technology Overview
Table 4.2. DNA-Encoded Libraries: Methods of Library Synthesis 
Table 4.3. DNA-Encoded Libraries: Developer Overview
Table 4.4. DNA-Encoded Libraries: Type of Service Offered
Table 4.5. DNA-Encoded Libraries: Supporting Companies
Table 5.1. DNA-Encoded Libraries: Partnerships and Collaborations, 2010-2019
Table 6.1. HitGen: Key Highlights
Table 6.2. HitGen: Recent Developments and Future Outlook
Table 6.3. X-Chem: Company Snapshot
Table 6.4. X-Chem: Recent Developments and Future Outlook
Table 6.5. Vipergen: Company Snapshot
Table 6.6. Vipergen: Recent Developments and Future Outlook
Table 6.7. DyNAbind: Company Snapshot
Table 6.8. DyNAbind: Recent Developments and Future Outlook 
Table 7.1. GPCR’s: List of Clinical / Preclinical Molecules 
Table 7.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
Table 8.1. Amgen: Company Snapshot
Table 8.2. AstraZeneca: Company Snapshot
Table 8.3. GSK: Company Snapshot
Table 8.4. Novartis: Company Snapshot
Table 8.5. Pfizer: Company Snapshot
Table 8.6. Roche: Company Snapshot
Table 9.1. Library Licensing Deal: Tranches of Milestone Payments
Table 9.2. DNA-Encoded Libraries: Average Upfront Payments and Average Milestone Payments (USD Million) 
Table 10.1. DNA-Encoded Libraries: Summary of the Competitive Insights 
Table 12.1. DNA-Encoded Libraries: Distribution by Library Size 
Table 12.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead 
Table 12.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis 
Table 12.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
Table 12.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
Table 12.6. DNA-Encoded Libraries: Distribution by Year of Establishment
Table 12.7. DNA-Encoded Libraries: Distribution by Company Size
Table 12.8. DNA-Encoded Libraries: Distribution by Geographical Location 
Table 12.9. DNA-Encoded Libraries: Distribution by Type of Service Offered 
Table 12.10. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019
Table 12.11. Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.12. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 12.13. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner 
Table 12.14. Partnerships and Collaborations: Most Active Players 
Table 12.15. Most Popular Technologies: Distribution by Number of Partnerships
Table 12.16. Partnerships and Collaborations: Analysis by Local and International Distribution
Table 12.17. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
Table 12.18. Case Study: Popular Drug Discovery Methods, 2016-2017

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. Abilita Bio
  3. Actelion Pharmaceuticals
  4. Aduro Biotech
  5. Alexion Pharmaceuticals
  6. Almirall
  7. Amgen
  8. AMRI
  9. Arvinas
  10. Asinex
  11. Astellas Pharma
  12. AstraZeneca
  13. BASF
  14. Bayer 
  15. BeiGene
  16. Biogen
  17. Biokine Therapeutics
  18. BioLineRx
  19. Biotage
  20. Bristol-Myers Squibb
  21. BOC Sciences
  22. Boehringer Ingelheim
  23. Broad Institute
  24. California Institute for Biomedical Research (Calibr)
  25. Cancer Research Technology 
  26. Cantex Pharmaceuticals
  27. Central European Institute of Technology (CEITEC)
  28. Charles River Laboratories 
  29. Checkpoint Therapeutics
  30. ChemAxon
  31. ChemRoutes
  32. Chem-Space
  33. Circle Pharma
  34. Clovis Oncology
  35. Cocrystal Pharma
  36. Columbia University
  37. ComInnex
  38. Confo Therapeutics
  39. Cyclofluidic
  40. Daiichi Sankyo
  41. DELopen
  42. Deluge Biotechnologies
  43. DiCE Molecules
  44. DNA Technologies and Expression Analysis Core, University of California
  45. DyNAbind
  46. Edelris
  47. Eli Lilly 
  48. Enamine
  49. Ensemble Therapeutics
  50. ETH Zurich
  51. Exo therapeutics
  52. FORMA Therapeutics
  53. Galapagos
  54. Genentech
  55. Gilead Sciences
  56. Global Blood Therapeutics
  57. GlycoMimetics 
  58. Heptares Therapeutics
  59. HitGen
  60. HotSpot Therapeutics
  61. InterX Technologies
  62. Janssen Biotech
  63. Jeil Pharmaceutical
  64. Jiangsu Hengrui Medicine
  65. Johnson & Johnson
  66. Kymera Therapeutics
  67. LEO Pharma
  68. Liverpool ChiroChem
  69. LG Chem
  70. LGC, Bioresearch Technologies
  71. Macroceutics
  72. Maruho
  73. MD Anderson Cancer Center
  74. Medivation
  75. Merck
  76. Mitsubishi Tanabe Pharma
  77. Navitor Pharmaceuticals 
  78. NetVation
  79. Northwestern University
  80. Novartis 
  81. Nuevolution
  82. Nurix Therapeutics
  83. OMass Therapeutics
  84. Ono Pharmaceutical 
  85. Orbit Discovery
  86. Otsuka Pharmaceutical
  87. Pfizer
  88. Pharmaceutical Product Development
  89. Pharmaron
  90. Philochem
  91. PhoreMost
  92. PhyNexus
  93. Plexium
  94. Polyphor
  95. Praecis Pharmaceuticals
  96. PROvendis
  97. PsyBrain
  98. Radikal Therapeutics
  99. Roche
  100. Sanofi
  101. Servier
  102. Simcere Pharmaceutical
  103. Sun Pharma Advanced Research Company (SPARC)
  104. SpiroChem
  105. Taiho Pharmaceutical
  106. Takeda Pharmaceutical
  107. Tasly
  108. Tesaro
  109. The Scripps Research Institute 
  110. University of California
  111. University of Manchester
  112. University of Pennsylvania
  113. Vertex Pharmaceuticals
  114. Vipergen
  115. Viva Biotech
  116. Warp Drive Bio
  117. WuXi AppTec
  118. X-Biotix Therapeutics
  119. X-Chem
  120. X4 Pharmaceuticals

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com